...
tcrx-img

Tscan Therapeutics Inc, Common Stock

TCRX

NMQ

$4.77

+$0.13

(2.8%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$247.64M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
0
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.78
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$3.92 L
$9.69 H
$4.77

About Tscan Therapeutics Inc, Common Stock

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameTCRXSectorS&P500
1-Week Return15.78%2.3%1.73%
1-Month Return-2.45%-1.77%3.44%
3-Month Return-13.74%-6.07%7.02%
6-Month Return-45.42%2.45%13.38%
1-Year Return-7.92%12.17%32.25%
3-Year Return-39.77%10.46%29.27%
5-Year Return-54.57%46.4%90.61%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-1.08M10.14M13.54M21.05M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":5.15,"profit":true},{"date":"2021-12-31","value":48.18,"profit":true},{"date":"2022-12-31","value":64.3,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue519.00K20.58M3.33M5.14M88.15M[{"date":"2019-12-31","value":0.59,"profit":true},{"date":"2020-12-31","value":23.34,"profit":true},{"date":"2021-12-31","value":3.78,"profit":true},{"date":"2022-12-31","value":5.83,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(519.00K)(19.49M)6.81M8.40M(67.10M)[{"date":"2019-12-31","value":-6.18,"profit":false},{"date":"2020-12-31","value":-232.1,"profit":false},{"date":"2021-12-31","value":81.13,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-799.05,"profit":false}]
Gross Margin-(1796.50%)67.18%62.05%(318.80%)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-2674.05,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":92.35,"profit":true},{"date":"2023-12-31","value":-474.53,"profit":false}]
Operating Expenses14.21M27.32M58.78M80.17M114.51M[{"date":"2019-12-31","value":12.41,"profit":true},{"date":"2020-12-31","value":23.86,"profit":true},{"date":"2021-12-31","value":51.33,"profit":true},{"date":"2022-12-31","value":70.01,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(14.21M)(26.23M)(48.64M)(66.64M)(93.46M)[{"date":"2019-12-31","value":-1421000000,"profit":false},{"date":"2020-12-31","value":-2623300000,"profit":false},{"date":"2021-12-31","value":-4864100000,"profit":false},{"date":"2022-12-31","value":-6663600000,"profit":false},{"date":"2023-12-31","value":-9345800000,"profit":false}]
Total Non-Operating Income/Expense1.10M212.00K32.00K830.00K6.66M[{"date":"2019-12-31","value":16.57,"profit":true},{"date":"2020-12-31","value":3.18,"profit":true},{"date":"2021-12-31","value":0.48,"profit":true},{"date":"2022-12-31","value":12.46,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(13.66M)(26.13M)(48.63M)(66.22M)(89.22M)[{"date":"2019-12-31","value":-1365800000,"profit":false},{"date":"2020-12-31","value":-2612700000,"profit":false},{"date":"2021-12-31","value":-4862500000,"profit":false},{"date":"2022-12-31","value":-6622100000,"profit":false},{"date":"2023-12-31","value":-8921800000,"profit":false}]
Income Taxes(552.00K)(106.00K)3.09M(415.00K)5.19M[{"date":"2019-12-31","value":-10.63,"profit":false},{"date":"2020-12-31","value":-2.04,"profit":false},{"date":"2021-12-31","value":59.53,"profit":true},{"date":"2022-12-31","value":-7.99,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes(13.11M)(26.02M)(51.72M)(65.81M)(94.41M)[{"date":"2019-12-31","value":-1310600000,"profit":false},{"date":"2020-12-31","value":-2602100000,"profit":false},{"date":"2021-12-31","value":-5171644200,"profit":false},{"date":"2022-12-31","value":-6580600000,"profit":false},{"date":"2023-12-31","value":-9441110500,"profit":false}]
Income From Continuous Operations(13.66M)(26.13M)(48.64M)(66.22M)(88.33M)[{"date":"2019-12-31","value":-1365800000,"profit":false},{"date":"2020-12-31","value":-2612700000,"profit":false},{"date":"2021-12-31","value":-4864100000,"profit":false},{"date":"2022-12-31","value":-6622100000,"profit":false},{"date":"2023-12-31","value":-8832800000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(13.11M)(26.02M)(48.63M)(65.81M)(89.22M)[{"date":"2019-12-31","value":-1310600000,"profit":false},{"date":"2020-12-31","value":-2602100000,"profit":false},{"date":"2021-12-31","value":-4862500000,"profit":false},{"date":"2022-12-31","value":-6580600000,"profit":false},{"date":"2023-12-31","value":-8921800000,"profit":false}]
EPS (Diluted)--(9.98)(2.75)(1.89)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-998,"profit":false},{"date":"2022-12-31","value":-275,"profit":false},{"date":"2023-12-31","value":-189,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

TCRX
Cash Ratio 9.46
Current Ratio 9.56

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

TCRX
ROA (LTM) -23.36%
ROE (LTM) -55.92%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

TCRX
Debt Ratio Lower is generally better. Negative is bad. 0.34
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.66

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

TCRX
Trailing PE NM
Forward PE NM
P/S (TTM) 26.45
P/B 1.08
Price/FCF NM
EV/R 7.14
EV/Ebitda 0.39

FAQs

What is Tscan Therapeutics Inc share price today?

Tscan Therapeutics Inc (TCRX) share price today is $4.77

Can Indians buy Tscan Therapeutics Inc shares?

Yes, Indians can buy shares of Tscan Therapeutics Inc (TCRX) on Vested. To buy Tscan Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TCRX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Tscan Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Tscan Therapeutics Inc (TCRX) via the Vested app. You can start investing in Tscan Therapeutics Inc (TCRX) with a minimum investment of $1.

How to invest in Tscan Therapeutics Inc shares from India?

You can invest in shares of Tscan Therapeutics Inc (TCRX) via Vested in three simple steps:

  • Click on Sign Up or Invest in TCRX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Tscan Therapeutics Inc shares
What is Tscan Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Tscan Therapeutics Inc (TCRX) is $9.69. The 52-week low price of Tscan Therapeutics Inc (TCRX) is $3.92.

What is Tscan Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Tscan Therapeutics Inc (TCRX) is

What is Tscan Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Tscan Therapeutics Inc (TCRX) is 1.08

What is Tscan Therapeutics Inc dividend yield?

The dividend yield of Tscan Therapeutics Inc (TCRX) is 0.00%

What is the Market Cap of Tscan Therapeutics Inc?

The market capitalization of Tscan Therapeutics Inc (TCRX) is $247.64M

What is Tscan Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Tscan Therapeutics Inc is TCRX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top